Evidence map›Paper›PMID 27058623›Full record

ArticleOncotarget2016

The physical interaction of p53 and plakoglobin is necessary for their synergistic inhibition of migration and invasion.

Mahsa Alaee, Amarjot Padda, Vahedah Mehrabani, Lucas Churchill, Manijeh Pasdar

Abstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Junction Plakoglobin - A Dual-Role Player in Cancer Biology.International journal of surgery (London, England) · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mahsa AlaeeDepartment of Oncology, University of Alberta, Edmonton, AB, T6G1Z2, Canada.
Amarjot PaddaDepartment of Oncology, University of Alberta, Edmonton, AB, T6G1Z2, Canada.
Vahedah MehrabaniDepartment of Oncology, University of Alberta, Edmonton, AB, T6G1Z2, Canada.
Lucas ChurchillDepartment of Oncology, University of Alberta, Edmonton, AB, T6G1Z2, Canada.
Manijeh PasdarDepartment of Oncology, University of Alberta, Edmonton, AB, T6G1Z2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plakoglobin (PG) is a paralog of β-catenin with similar adhesive, but contrasting signalling functions. Although β-catenin has well-known oncogenic function, PG generally acts as a tumor/metastasis suppressor by mechanisms that are just beginning to be deciphered. Previously, we showed that PG interacted with wild type (WT) and a number of mutant p53s, and that its tumor/metastasis suppressor activity may be mediated, at least partially, by this interaction. Here, carcinoma cell lines deficient in both p53 and PG (H1299), or expressing mutant p53 in the absence of PG (SCC9), were transfected with expression constructs encoding WT and different fragments and deletions of p53 and PG, individually or in pairs. Transfectants were characterized for their in vitro growth, migratory and invasive properties and for mapping the interacting domain of p53 and PG. We showed that when coexpressed, p53-WT and PG-WT cooperated to decrease growth, and acted synergistically to significantly reduce cell migration and invasion. The DNA-binding domain of p53 and C-terminal domain of PG mediated p53/PG interaction, and furthermore, the C-terminus of PG played a central role in the inhibition of invasion in association with p53.

Indexed as

CarcinomaCell Line, TumorCell Movementgamma CateninHumansNeoplasm InvasivenessTumor Suppressor Protein p53gamma CateninJUP protein, humanTP53 protein, humanTumor Suppressor Protein p53invasionmigrationp53plakoglobintumor/metastasis suppressor

Identifiers

PMID27058623
PMCPMC5042024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.